Neurological Manifestations Associated with Synthetic Cannabinoid Use - A Case Series Marwa Elnazeir, Siddharth Narayanan, Pradeepthi Badugu, Abid Hussain, Cody B. Stephens, Riwaj Bhagat, Christopher M. Jones, Wei Liu, Alexi R. Hernandez, Kerri S. Remmel and Adriana E. Palade The Open Neurology Journal, 2020, 14, 53-58. Doi : 10.2174/1874205X02014010053 Abstract : Background : Synthetic Cannabinoid (SC) use has emerged as a growing public health threat in the United States. Several unexpected cases, presenting with a constellation of unrelated symptoms, but all having toxicity linked to SC use, have been reported in the last decade (2010-2019). Methods : We report a cluster of several independent cases where patients were [...]
Lire la suiteCannabis (Marijuana) : Psychoactive Properties, Addiction, Therapeutic Uses, and Toxicity Sumanasekera W.K. and Spio K. Journal of Addictive Behaviors, Therapy and Rehabilitation, 2016, 5, 2, 1-9. Doi : 10.4172/2324-9005.10001562016 Abstract Background and Objectives : To analyze the existing literature on cannabis (marijuana) under several sub topics; history of use, addiction, mechanism of action, therapeutic uses, and adverse effects. Methods : A comprehensive literature search was conducted. Data sources include original research articles, systematic reviews and meta- analysis, and web-based references such as Drug strategy monographs and Merck Index. Data bases such as PubMed and Cinhal was used. References were from 1979 -2016. Hypothesis : Based on the [...]
Lire la suiteCannabinoids Rescue Cocaine-Induced Seizures by Restoring Brain Glycine Receptor Dysfunction Guichang Zou, Xin Zuo, Kai Chen, ..., Guangming Huang, Dan Liu, Wei Xiong Cell Reports, 2020, 30, 4209–4219 Doi : 10.1016/j.celrep.2020.02.106 In Brief Zou et al. identify the glycine receptor as a potential therapeutic target for cannabinoids in treating cocaine-induced seizures. The function of extra-synaptic glycine receptors in the prefrontal cortex and hippocampus is impaired by cocaine and rescued by cannabinoids, therefore leading to the therapeutic effects of cannabinoids in treating cocaine-induced seizures. Highlights Cannabinoids alleviate cocaine-induced seizures (CISs) by glycine receptors (GlyRs) Cannabinoid docking reduces hydrogen-bonding interaction between cocaine and GlyRs The prefrontal cortex and hippocampus [...]
Lire la suiteEtats-Unis : l’Epidiolex n’est plus une substance contrôlée Aurélien BERNARD Newsweed.fr, 8 avril 2020 https://www.newsweed.fr/etats-unis-lepidiolex-nest-plus-une-substance-controlee/ GW Pharmaceuticals a annoncé lundi que l’Epidiolex, un médicament à base de cannabidiol (CBD) utilisé dans le traitement de l’épilepsie, avait été retiré de l’annexe V de la Loi américaine sur les substances contrôlées par la Drug Enforcement Administration (DEA). Les personnes qui pourraient en bénéficier pourront dorénavant en obtenir plus facilement. GW a déclaré dans son communiqué qu’il « entamera maintenant le processus de mise en œuvre de ces changements au niveau de l’État et via le réseau de distribution EPIDIOLEX ». Comme pour de nombreux médicaments non-contrôlés, les malades ou leurs [...]
Lire la suiteBibliographie : Cannabidiol (CBD) Docteur Christian SUEUR, GRECC, avril 2020. voir aussi : Bibliographie : Cannabis et Cannabinoïdes en Psychiatrie, Bibliographie : Cannabinoïdes et neuroprotection Bibliographie : Cannabinoïdes et épilepsie Bibliographie : Interactions et antagonisme THC - CBD Bibliographie : Effets indésirables du Cannabis (thérapeutique) sur la Santé mentale Bibliographie : Cannabinoïdes, Dépression et Troubles de l’Humeur Bibliographie : Cannabinoïdes et PTSD Bibliographie : Cannabinoïdes et TSA/TED/psychoses infantiles Bibliographie : Cannabinoïdes et Maladies Neurodégénératives
Lire la suiteAbuse potential assessment of cannabidiol (CBD) in recreational polydrug users : A randomized, double-blind, controlled trial Kerri A. Schoedel, Isabella Szeto, Beatrice Setnik, Edward M. Sellers, Naama Levy-Cooperman, Catherine Mills, Tilden Etges, Kenneth Sommerville Epilepsy & Behavior, 2018, 88, 162–171. Doi : 10.1016/j.yebeh.2018.07.027 a b s t r a c t Rationale : Treatment with a highly purified oral solution of cannabidiol (CBD), derived from the plant Cannabis sativa L., demonstrated some evidence of central nervous system (CNS)-related adverse events in patients enrolled in phase 3 trials for treatment of childhood-onset epilepsy. Cannabidiol was categorized as a Schedule 1 substance by the United States Drug [...]
Lire la suiteA Review of Human Studies Assessing Cannabidiol’s (CBD) Therapeutic Actions and Potential C. Michael White The Journal of Clinical Pharmacology, 2019, 59, (7) 923–934 Doi : 10.1002/jcph.1387 Abstract Cannabidiol (CBD) is a highly touted product for many different disorders among the lay press. Numerous CBD products are available, ranging from a US Food and Drug Administration (FDA) approved product called Epidiolex to products created for medical marijuana dispensaries and products sold in smoke shops, convenience stores, and over the Internet.The legal status of the non–FDA approved products differs depending on the source of the CBD and the state,while the consistency and quality of the non–FDA-approved [...]
Lire la suiteAnticonvulsive Properties of Cannabidiol in a Model of Generalized Seizure Are Transient Receptor Potential Vanilloid 1 Dependent Royston A. Gray, Colin G. Stott, Nicholas A. Jones, Vincenzo Di Marzo, and Benjamin J. Whalley Cannabis and Cannabinoid Research, 2019,1-5. Doi : 10.1089/can.2019.0028 Abstract Introduction : Highly purified cannabidiol (CBD) (approved as Epidiolex in the United States) has demonstrated efficacy with an acceptable safety profile in patients with Lennox–Gastaut or Dravet syndrome in four randomized controlled trials. CBD possesses affinity for many target classes with functional effects relevant to the pathophysiology of many disease types, including epilepsy. Although the mechanism of action of CBD underlying the reduction [...]
Lire la suiteCannabis for pediatric epilepsy : protocol for a living systematic review Jesse Elliott, Deirdre DeJean, Tammy Clifford, Doug Coyle, Beth Potter, Becky Skidmore, Christine Alexander, Alexander E. Repetski, Bláthnaid McCoy and George A. Wells Systematic Reviews, 2018, 7, 95 doi : 10.1186/s13643-018-0761-2 Abstract Background : Pediatric epilepsy, including treatment-resistant forms, has a major effect on the quality of life, morbidity, and mortality of affected children. Interest has been growing in the use of medical cannabis as a treatment for pediatric epilepsy, yet there has been no comprehensive review of the benefits and harms of cannabis use in this population. In this systematic review, we will [...]
Lire la suiteBibliographie : Cannabinoïdes et Epilepsie Docteur Christian SUEUR, GRECC, version actualisée, mars 2020
Lire la suite